Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 6 | BMC Cancer

Fig. 6

From: Vascular disruptive agent OXi4503 and anti-angiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis

Fig. 6

OXi4503, Sunitinib and combination treatments induce EMT in the surviving tumor cells. Formalin-fixed control and treated tumor sections were stained with antibodies to E-cadherin, ZEB1, or Vimentin. Positive expression is detected by the brown staining. Scale bar = 50 μm. L = liver, T = live tumor. NT = necrotic tumor. Images are representative for each treatment group (n ≥ 5 animals)

Back to article page